Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2020 ( 2 )

2019 ( 38 )

2018 ( 129 )

2017 ( 120 )

Custom range...

Search Results: 1 - 10 of 6484 matches for " transplants [adverse effects] "
All listed articles are free for downloading (OA Articles)
Page 1 /6484
Display every page Item
Importancia del estudio del quimerismo en el trasplante alogénico de médula ósea
Amor Vigil,Ana M; Martínez Antu?a,Gisela;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2003,
Abstract: since the hematopoietic transplantation was performed for the first time, the importance of knowing chimerism was underlined. the present paper updates the concepts of chimerism, its classification and the different ways to determine it. the most recommended is the highly polymorphic area amplification in the dna using the polymerase chain reaction technique. this technique has allowed carrying out studies on the evolution of chimera, to relate the set level of chimerism with the graft behaviour and the graft-versus-host disease under different conditioning. it has also made it possible to early detect relapse of transplanted patients and the prompt administration of additional immunotherapy. finally, the paper presents the recommendations of the american society of blood and bone marrow transplantation for standardizing the study of chimerism in the therapy centers
Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings  [PDF]
Leo Niskanen, Janne Suvisaari, Jaana Suvisaari, Anna But, Jari Haukka
Pharmacology & Pharmacy (PP) , 2013, DOI: 10.4236/pp.2013.43046

Purpose: The aim was to study discontinuation of statin treatment, especially with respect to clinical characteristics and adverse effect measured by clinical laboratory tests indicating muscle damage (plasma creatine kinase, CK) and liver AEs (plasma alanine aminotransferase, ALAT). Methods: The initial study population included 60,488 individuals who had purchased first time statin prescription in Helsinki-Uusimaa region between 01-01-2007 and 31-12-2009. The follow-up started when first statin prescription was purchased and ended 31-12-2009 or death, which ever occurred first. From this population 54,172 individuals were defined to eligible to study population of this study. Clinical laboratory measurements were obtained from Helsinki-Uusimaa University Hospital (HUSLAB) that which provides the laboratory tests for the Helsinki-Uusimaa region serving about a population of 1.5 million. Results: In this fairly large real-life study the occurrence of ALAT-AE and mild CK-elevations after initiation of first statin treatments were relatively low. Increasing age and the presence of co-morbidities increased the risk of these AEs. Further, the ALAT-AEs implied increased risk of discontinuation of treatment. Diabetic patients discontinued treatment more often than non-diabetics, whereas the presence of other chronic conditions implied higher persistence of statin treatment. Conclusions: It is essential that those who would benefit from statin therapy actually are treated and by far in most patients treatment seems to be safe and well tolerated. For those who cannot tolerate statins new therapeutic options are needed.

Efficacy and Safety of Dexmedetomidine during Anesthesia Induction of Patients with Intracranial Tumor: A Preliminary Observational Trial  [PDF]
Jiangbei Cao, Wenzhu Shi, Weidong Mi, Hong Zhang
Pharmacology & Pharmacy (PP) , 2013, DOI: 10.4236/pp.2013.48084
Abstract: Background: The efficacy and safety of dexmedetomidine during the anesthesia induction of intracranial tumor patients remain unknown. We wondered whether loading infusion of dexmedetomidine 1 μg/kg over 10 min to intracranial tumor patients was as efficient and safe as to those abdominal disease patients. Methods: Patients aged 18-60 years, male or female, ASA I or II, scheduled for intracranial tumor resection (Group N, n = 30) or abdominal operation (Group A, n = 30) were enrolled in this observational trial. Dexmedetomidine was administrated with a loading dosage of 1 μg/kg over 10 min following with continuous infusing of 0.5 μg/kg/h. Fentanyl, propofol and rocuronium were sequentially administered for anesthesia induction. Heart rate (HR), blood pressure (BP), pulse oxygen saturation (SpO2), bispectral index (BIS) and other adverse effects were recorded from the beginning of loading infusion of dexmedetomidine to the end of endotracheal intubation. Results: Among with loading infusion, HR and BIS value decreased and were significantly lower at the end of infusion than before infusion (P < 0.01), but BP did not (P > 0.05). One patient of Group N dropped out from this trial because of a serious headache. 14 of 29 patients during dexmedetomidine loading infusion suffered hypoxemia (SpO2 < 90%) in Group N, which was higher than 6 of 30 of in Group A (P < 0.05). No other side effects were recorded.
Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia)  [PDF]
Zahra Mozaheb, Maeedeh Javani
Health (Health) , 2014, DOI: 10.4236/health.2014.610113
Abstract: Sixty patients with Chronic Myeloid Leukemia (CML) who were on oral imatinib were included in this study. The study aimed to evaluate patients characteristic, tolerability and efficacy and clinical outcome in Iranian patients who have been treated with generic imatinib. The median age of patients was 48 years, and the median follow up was 44 months. 94% of patients achieved complete hematologic response (CHR) during the 3 months of beginning imatinib, and after 12 - 24 months of imatinib therapy 46.8% achieved molecular response. The most common non-hematologic toxicity was fluid retention (64%), fatigue (43%) and moderate to severe hematologic side effect included anemia 10%, neutropenia 10%, and thrombocytopenia 6.6%. About 13% of patients transformed into accelerated phase (AP) or blastic crisis (BC) and the death rate during this period was 7%. In conclusion, there is heterogeneity in different areas in characteristic of CML (especially in age), and also response rate and side effect of patients with CML that treated with imatinib are different.
Risk Factors for Cancer Chemotherapy-Induced Hiccups (CIH)  [PDF]
Ryuichiro Hosoya, Ippei Tanaka, Reiko Ishii-Nozawa, Takeshi Amino, Tomoyuki Kamata, Seiichi Hino, Hajime Kagaya, Yoshihiro Uesawa
Pharmacology & Pharmacy (PP) , 2018, DOI: 10.4236/pp.2018.98026
Abstract: Background: Hiccups are common somatic side effects of medication. Our previous analysis of the clinical risk factors for hiccups identified chemotherapy as a factor related to hiccup risk. Therefore, in the present study, we investigated the risk factors for hiccups associated with chemotherapy. Methods: We included all patients who received cancer chemotherapy and were hospitalized at the Musashino Red Cross Hospital between April 2014 and December 2014. We investigated patient demographics, physical characteristics, and other clinical factors to identify the risk factors for chemotherapy-induced hiccups (CIH). We conducted univariate and multivariable analysis to compare the CIH group and the non-CIH and determined risk factors of CIH. Results: Hiccups were identified in 48 of 292 patients with an incidence rate of 16.4%. Univariate analysis revealed that the male gender, pain, and nausea and vomiting were related to CIH. It also showed that cisplatin, pemetrexed, gemcitabine, etoposide, dexamethasone, and metoclopramide were related to CIH.A correlation which was found with doses of cisplatin, pemetrexed, gemcitabine, and etoposide. Multivariable analysis identified male gender (OR, 72.69; 95% CI, 6.95 - 757.64), nausea and vomiting (OR, 52.01; 95% CI, 3.93 - 447.13), dexamethasone (OR, 4.55; 95% CI, 1.12 - 16.91), cisplatin (OR, 3.84; 95% CI, 1.52 - 9.70), and etoposide (OR, 3.72; 95% CI, 1.14 - 12.11) as independent risk factors for hiccups. Conclusions: The present study is the first one to report risk factors for the development of CIH. Our results suggest that male gender, having nausea, and the drugs dexamethasone, cisplatin, and etoposide are important risk factors for CIH. These results may assist in elucidation of the underlying mechanisms and guide therapy to reduce hiccup risk.
Does Low-Dose Intravenous Methylprednisolone Pulse Therapy Produce Unacceptable Adverse Effects in Children?  [PDF]
Daishi Hirano, Shuichiro Fujinaga, Amane Endo, Tsuneki Watanabe, Hiroyuki Ida
Open Journal of Nephrology (OJNeph) , 2013, DOI: 10.4236/ojneph.2013.34033

Background: Intravenous methylprednisolone pulse therapy has been used since the late 1960s for acute transplant rejection or severe renal involvement in systemic lupus erythematosus and primary glomerulonephritis. However, reports of serious adverse effects such as life-threatening cardiac arrhythmias and sudden death raise questions about its safety. Objective: To investigate the incidence of significant adverse effects associated with low-dose methylprednisolone pulse therapy (LDMPT) in pediatric patients. Methods: We retrospectively analyzed adverse effects during and after LDMPT in 68 patients (median age: 11.4 years; 43% male) with various glomerular diseases who were admitted to Saitama Childrens Medical Center between April 2007 and December 2010. LDMPT consisted of pulse methylprednisolone (15-20 mg/kg; maximum 600 mg/d) for 3 consecutive days weekly for 2-3 weeks. Results: Although adverse effects occurred in 54 of 68 patients (79%), most were mild and transient. Transient glycosuria was noted in 46 patients (68%), hypertension in 6 (9%), elevated intraocular pressure in 6 (9%), hypokalemia in 5 (7%), and liver damage in 2 (3%). No late-onset adverse effects such as osteoporotic fractures, steroid diabetes mellitus, or short stature were observed. Conclusion: LDMPT appears to be relatively safe and well tolerated in children with various glomerular

Molde br?nquico devido ao uso de interferon peguilado e ribavirina
Garcia, Eduardo;Silva Junior, ?ngelo Ferreira da;Schorr, Fabíola;Hota, Milene;Brizzi, Ricardo Gondim;Silva, André Barreto da;
Jornal Brasileiro de Pneumologia , 2009, DOI: 10.1590/S1806-37132009000700014
Abstract: we report the case of a 50-year-old male patient with a rare profile: bronchial casts associated with the use of pegylated interferon and ribavirin. the patient sought treatment in a pulmonology clinic with a history of progressive dyspnea for four months that had evolved to progressive cough followed by frequent and abundant elimination of bronchial casts. the patient was initially treated with bronchodilators, as well as with oral and inhaled corticosteroids. fiberoptic bronchoscopy, bronchoalveolar lavage and sputum analysis were carried out but did not contribute to the elucidation of the diagnosis. the symptoms developed while the patient was receiving pegylated interferon and ribavirin for the treatment of hepatitis c. the symptoms resolved 30 days after the discontinuation of the treatment. to our knowledge, this is the first report of bronchial casts caused by the use of pegylated interferon and ribavirin.
Minimizing side effects of systemic corticosteroids in children
Deshmukh C
Indian Journal of Dermatology, Venereology and Leprology , 2007,
Abstract: Corticosteroids are potent drugs used in management of various inflammatory and autoimmune disorders. The antiinflammatory effects of corticosteroids cannot however be separated from their metabolic effects. Children are more vulnerable to their side effects, particularly the effects on growth, immunity and adrenal suppression. It is essential for the treating physician to be aware of the side effects and the measures to be taken to minimize them. A side effect that is unique to children is growth suppression, which is helped by alternate day treatment. Administration of small doses of prednisolone (10-15 mg/day or < 0.5 mg/kg/day single dose) on alternate days, does not slow growth velocity significantly. The potency of dexamethasone and betamethasone in suppressing growth is nearly 18 times higher than that of prednisolone. There is some evidence that the administration of growth hormone can reverse these changes.
Ulcera??o das placas psoriáticas - efeito cutaneo adverso do metotrexato em altas doses no tratamento da psoríase: relato de três casos
Ataíde, Deborah Skusa de Torre;Esmanhoto, Luciana Dorigo Kucharski;Helmer, Karin Adriane;Guerra, Ivette Renata Caron;Guimar?es, Christine de Campos Graf;Moritz, Sandra;
Anais Brasileiros de Dermatologia , 2003, DOI: 10.1590/S0365-05962003000600011
Abstract: the authors report three cases of psoriatic patients who inadvertently increased methotrexate doses and presented with ulceration of cutaneous psoriatic lesions. adverse cutaneous effects of methotrexate are rare. at times they may be dose related, while at others they are idiosyncratic, or related to drug metabolism or drug interactions.
Hiponatremia secundaria a diuréticos
Las Heras Mosteiro,J.; Taboada Taboada,M.;
Medifam , 2001, DOI: 10.4321/S1131-57682001000500008
Abstract: the most important cause of hyponatremia in adults is diuretic′s therapy. effective use of diuretics by the family doctor, requires knowledge of the pharmacology of each diuretic agent coupled with an understanding of pathophysiology of the patient′s disease. we report a case of 70-years old female who had heart failure class iii-iv new york heart association (nyha) secondary to multivalvular cardiomyopathy. she had implanted vvi medtronic pacemaker for sick-sinus syndrome. treatment with furosemide, spironolactone, enalapril, digoxine and oral anticoagulant. she presented a clinical pattern of disorientation and a swich-off episode with severe hyponatremia.
Page 1 /6484
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.